Circle Pharma has initiated a clinical trial to evaluate
the safety and efficacy of CID-078, as monotherapy
across a range of solid tumors.
This first-in-human, Phase 1, multi-center, open-label, dose-escalation, dose-expansion study is evaluating CID-078 in patients with advanced cancer. This study is being conducted in two parts. The primary purpose of Part 1 is to evaluate safety and identify one or more doses for expansion (Part 2). Part 2 will evaluate anti-tumor efficacy and further characterize the safety, tolerability, and pharmacokinetics of the CID-078 dose(s) selected in Part 1.
Visit ClinicalTrials.gov (NCT06577987) for more information about this trial.
CID-078 is an investigational agent whose safety and efficacy in solid tumor malignancies has not been evaluated by the FDA or any other regulatory Agency.
Subscribe to our News Alerts